Havrix

Havrix is a prescription‑only injectable solution that contains an inactivated hepatitis A virus combined with algeldrate as a stabilizer. The vaccine is formulated for intramuscular administration and is marketed in the European Union. Havrix belongs to the vaccine drug class (ATC code J07BC01) and works by stimulating the body’s immune system to produce protective antibodies against hepatitis A virus. It is used to prevent hepatitis A infection.

Havrix is indicated for the active immunization against hepatitis A in individuals who have not previously been exposed to the virus.

- Primary prevention of hepatitis A infection in adults and children aged 12 months and older. - Pre‑travel protection for persons traveling to regions where hepatitis A is endemic. - Use in outbreak settings to quickly establish herd immunity. - Administration to individuals with chronic liver disease to reduce risk of severe hepatitis A. - Recommended for healthcare workers and others at occupational risk of exposure.

The safety profile of Havrix reflects the typical reactions observed with inactivated viral vaccines.

Common: - Mild pain, redness, or swelling at the injection site that usually resolves within a few days. - Low‑grade fever, often accompanied by chills, occurring within 24 hours after vaccination. - Headache that may be transient and respond to over‑the‑counter analgesics. - Fatigue or a general feeling of tiredness lasting one to two days. - Mild muscle aches or joint discomfort in the days following injection.

Serious: - Severe allergic reaction (anaphylaxis) characterized by difficulty breathing, hives, swelling of the face, throat, or tongue, and a rapid pulse. - Neurological events such as Guillain‑Barré syndrome, presenting with muscle weakness and tingling sensations, reported rarely. - Persistent high fever, seizures, or other serious systemic reactions, which are extremely uncommon.

Before receiving Havrix, certain health considerations should be reviewed to ensure safe and effective immunization.

- Confirm that the individual has not previously received a complete hepatitis A vaccination series. - Defer vaccination in persons with a known severe allergy to any component of the product, including algeldrate. - Postpone administration during an acute moderate or severe febrile illness. - Discuss pregnancy and breastfeeding status with a healthcare professional, as safety data are limited. - Evaluate immune status; immunocompromised patients may have a reduced antibody response.

Havrix does not have many documented drug‑drug interactions, but certain substances and conditions may influence its administration or effectiveness.

Avoid: - Concurrent administration of other live vaccines at the same anatomical site. - Use of immunosuppressive therapy that may markedly diminish the antibody response.

Use with caution: - Concurrent use of systemic corticosteroids or disease‑modifying antirheumatic drugs; monitor antibody levels. - Administration in individuals receiving blood products or immunoglobulins; consider timing to avoid interference. - Vaccination in patients undergoing chemotherapy; schedule appropriately to achieve optimal immunity. - Patients with chronic kidney disease on dialysis should be observed for any unusual local or systemic reactions.